Lantern Pharma Secures Key Patent for Biomarker-Guided Cancer Therapy
Event summary
- Lantern Pharma received a Notice of Allowance from the USPTO for a patent covering biomarker-guided treatment with LP-184 (Zirdafulven) in multiple solid tumor cancers.
- The patent covers methods of treating ovarian, primary liver, kidney, or thyroid cancer based on elevated expression of PTGR1, PTPN14, and ASPH genes.
- Lantern's AI-driven RADR® platform identified the biomarker signature for LP-184's development.
- LP-184 demonstrated a 45% disease control rate in a Phase 1a trial involving 63 patients with advanced solid tumors.
The big picture
Lantern Pharma's patent approval underscores the growing intersection of AI and precision oncology, enabling more targeted cancer therapies. The company's ability to leverage genomic data and machine learning through its RADR® platform positions it at the forefront of a shift towards biomarker-guided treatments, potentially reducing development timelines and increasing success rates in clinical trials.
What we're watching
- Clinical Trial Expansion
- How the patent approval will accelerate Lantern Pharma's plans for multiple precision oncology Phase 1b/2 trials in advanced aggressive and rare cancers during 2026.
- Patent Portfolio Growth
- Whether Lantern Pharma can sustain its intellectual property strategy through additional filings covering further indications and biomarker-guided applications of LP-184.
- Regulatory Milestones
- The pace at which LP-184 advances through regulatory pathways, given its FDA Fast Track and Orphan Drug Designations.
Related topics